about
Cross-regulation of TNF and IFN-alpha in autoimmune diseasesRegulation of Dendritic Cell Function in InflammationPsoriasis assessment tools in clinical trials.Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis.The role of T cells in cutaneous autoimmune disease.Infliximab for the treatment of psoriasis.Biologic agents in psoriasis.Treatment of inflammatory dermatoses by tumour necrosis factor antagonists.Treating psoriasis with adalimumab.Biologic therapeutics in the treatment of psoriasis. Part 1: review.Infliximab for the treatment of plaque psoriasis.Clinical Evaluation of Humira® Biosimilar ONS-3010 in Healthy Volunteers: Focus on Pharmacokinetics and Pharmacodynamics.Angiogenesis drives psoriasis pathogenesis.Decreased levels of metalloproteinase-9 and angiogenic factors in skin lesions of patients with psoriatic arthritis after therapy with anti-TNF-alpha.Managing Scalp Psoriasis: An Evidence-Based Review.Five-year experience with infliximab: Follow up of the product familiarisation program.Roxithromycin downregulates production of CTACK/CCL27 and MIP-3α/CCL20 from epidermal keratinocytes.Novel anti-inflammatory treatments for asthma.Biologics in dermatology: adverse effects.Current concepts in the pathogenesis of psoriasis.Is there a role for tumor necrosis factor-alpha inhibitors and especially thalidomide in dermatology?Ultrastructural findings and tumor necrosis factor-alpha and intercellular adhesion molecule-1 expression in psoriasis patients before and after oral cyclosporin A therapy.Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseasesA descriptive analysis of real-world treatment patterns of innovator (Remicade) and biosimilar infliximab in an infliximab-naïve Turkish populationEffective Therapy with Anti-TNF- in Patients with Psoriatic Arthritis Is Associated with Decreased Levels of Metalloproteinases and Angiogenic Cytokines in the Sera and Skin Lesions
P2860
Q24556513-D62D42E1-9578-4ADC-9DA0-3B6620C99AF7Q26800988-4A3158B4-D7BF-4B16-B0E9-9D8DD60F7C22Q35579443-6440A909-D111-4CC2-B508-03F6C2F3DB11Q35893167-26A68637-B649-49A0-BBD5-650035A7FEEBQ36277428-3821B2B4-3D54-48DA-9CCF-3FC20AF4B8F9Q36541961-B3E00BEE-25E4-498E-802F-843AC4BA61E8Q36620700-359C80EF-6E5A-458C-BB51-DBB0424DB385Q36633460-8168D2B3-6600-4972-B253-D8F3CF1694F6Q36823592-1D5F6BAC-A7F3-44DF-87B9-8BE21EED0770Q36826201-9DA9B1D1-B771-459E-8208-1C5A367B0172Q37307554-9C018F8B-FBB8-45B5-B851-4F433CD15DAAQ37443755-77685DF7-988C-45F2-B424-033B7E3E2BA3Q37534974-62044C65-5665-4EFB-A454-A1FF5BBC4639Q38582187-1D02B5B6-2FB1-43C2-A1A4-EF40EC35D99AQ38960080-DBAC6B96-5D69-4992-8754-67F0031F1997Q38963492-1EEE7E8E-8CE4-4B0C-8B99-8926F6E309C0Q39681071-22481402-E86C-4962-A670-D27F1DC4068CQ40041782-1BD93B78-7135-42DB-8FD4-ED7E18B85248Q41120913-0885BD76-68FF-4C60-A8F7-D739900D379EQ42283126-EC4EAD84-9C0D-45B7-9532-0A6B51410A25Q45226912-4511F533-679B-4571-90DA-C3ABAE5D1288Q46975812-278995D2-FD03-45A9-9A29-1CD9CE93048BQ57167308-8E7F2F5D-020E-49B8-9FD6-152741CB13F0Q57484897-86146F03-85ED-440C-B60E-DBD6E968A284Q59154938-6953AA6F-F50C-427B-A076-1F499B03613B
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Infliximab for psoriasis.
@ast
Infliximab for psoriasis.
@en
Infliximab for psoriasis.
@nl
type
label
Infliximab for psoriasis.
@ast
Infliximab for psoriasis.
@en
Infliximab for psoriasis.
@nl
prefLabel
Infliximab for psoriasis.
@ast
Infliximab for psoriasis.
@en
Infliximab for psoriasis.
@nl
P1476
Infliximab for psoriasis.
@en
P2093
Alice B Gottlieb
P304
P356
10.1016/S0190-9622(03)01143-5
P407
P433
P577
2003-08-01T00:00:00Z